Repatha and Chronic kidney disease - a phase IV clinical study of FDA data

Summary:

Chronic kidney disease is reported as a side effect among people who take Repatha (evolocumab), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Nexium, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Chronic kidney disease when taking Repatha. It is created by eHealthMe based on reports of 155,838 people who have side effects when taking Repatha from the FDA, and is updated regularly.

What is Repatha?

Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 156,258 Repatha users. Check the latest studies of Repatha.

What is Chronic kidney disease?

Chronic kidney disease is found to be associated with 1,829 drugs and 1,371 conditions by eHealthMe. Check the latest studies of Chronic kidney disease.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

155,838 people reported to have side effects when taking Repatha.
Among them, 81 people (0.05%) have Chronic kidney disease.

Could Repatha cause Chronic kidney disease?

Among these 81 people:

How long have people been on Repatha when they have Chronic kidney disease? *

What is the gender of people who have Chronic kidney disease when taking Repatha? *

female: 52.11 %
male: 47.89 %

What is the age of people who have Chronic kidney disease when taking Repatha? *

What are other drugs people take besides Repatha? *

What are other side effects people have besides Chronic kidney disease? *

Acute Kidney Failure: 18 people, 22.22%
Stress And Anxiety: 14 people, 17.28%
Pain: 11 people, 13.58%
Emotional Distress: 10 people, 12.35%
Depression: 9 people, 11.11%
Anaemia (lack of blood): 8 people, 9.88%
Anhedonia (inability to experience pleasure from activities usually found enjoyable): 8 people, 9.88%
Fatigue (feeling of tiredness): 8 people, 9.88%
Urinary Tract Infection: 6 people, 7.41%
Osteopenia (a condition where bone mineral density is lower than normal): 5 people, 6.17%

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 20 people, 24.69%
Pain: 15 people, 18.52%
Neuralgia (pain in one or more nerves): 12 people, 14.81%
Hyperlipidaemia (presence of excess lipids in the blood): 12 people, 14.81%
Diabetes: 12 people, 14.81%
High Blood Pressure: 11 people, 13.58%
Blood Pressure Abnormal: 10 people, 12.35%
Hiv Infection: 10 people, 12.35%
Stable Angina (a constant chest pain): 8 people, 9.88%
Indigestion: 7 people, 8.64%

* Approximation only. Some reports may have incomplete information.

Do you take Repatha and have Chronic kidney disease?

- Check whether Chronic kidney disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Repatha:

Repatha (156,258 reports)

Browse all side effects of Repatha:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chronic kidney disease:

Chronic kidney disease (1,829 drugs)

Browse all the conditions that are associated with Chronic kidney disease:

Chronic kidney disease (1,371 conditions)

Related publications that referenced our studies

Aalaei-Andabili, S. H., Umer, M., & Keeley, E. C., "An Adult Woman With Stage 4 Chronic Kidney Disease and a Diffuse Rash", JAMA cardiology, 2019 Jan .
Aalaei-Andabili, S. H., Umer, M., & Keeley, E. C., "An Adult Woman With Stage 4 Chronic Kidney Disease and a Diffuse Rash", JAMA cardiology, 2019 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on evolocumab (the active ingredients of Repatha) and Repatha (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.